MDACC Study No:2011-0587 ( NCT No: NCT01349036)
Title:A Phase 2 Study of Orally Administered PLX3397 in Patients With
Recurrent Glioblastoma
Principal Investigator:John DeGroot
Treatment Agent:PLX3397
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if PLX3397 can help to
control glioblastoma. Researchers also want to learn more about how much study
drug is in the body at different time points. The safety of this drug will
also be studied.

PLX3397 is designed to block several proteins that are important to the growth,
division, and spread of cancer cells, which may cause the cells to die.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase II
Treatment Agents:PLX3397
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Plexxikon Inc
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults